Hybrid protein-synthetic polymer nanoparticles for drug delivery

Adv Protein Chem Struct Biol. 2015:98:93-119. doi: 10.1016/bs.apcsb.2014.12.003. Epub 2015 Mar 13.

Abstract

Among the most common nanoparticulate systems, the polymeric nanocarriers have a number of key benefits, which give a great choice of delivery platforms. Nevertheless, polymeric nanoparticles possess some limitations that include use of toxic solvents in the production process, polymer degradation, drug leakage outside the diseased tissue, and polymer cytotoxicity. The combination of polymers of biological and synthetic origin is an appealing modern strategy for the production of novel nanocarriers with unprecedented properties. Proteins' interface can play an important role in determining bioactivity and toxicity and gives perspective for future development of the polymer-based nanoparticles. The design of hybrid constructs composed of synthetic polymer and biological molecules such as proteins can be considered as a straightforward tool to integrate a broad spectrum of properties and biofunctions into a single device. This review discusses hybrid protein-synthetic polymer nanoparticles with different structures and levels in complexity and functionality, in view of their applications as drug delivery systems.

Keywords: Drug delivery; Hybrid nanoparticles; Peptides; Proteins; Synthetic polymers.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacology
  • Drug Delivery Systems / methods*
  • Humans
  • Micelles
  • Nanoparticles / chemistry*
  • Nanoparticles / ultrastructure
  • Polyesters / chemistry*
  • Polyethylene Glycols / chemistry*
  • Polyglutamic Acid / chemistry*
  • Proteins / chemistry*
  • Static Electricity

Substances

  • Antineoplastic Agents
  • Micelles
  • Polyesters
  • Proteins
  • Polyglutamic Acid
  • Polyethylene Glycols
  • Doxorubicin